drugset / Trial / NCT06634589
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with tacabrutideg in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with separate substudies. This study currently includes four substudies, and more substudies may be added as other combination agents are identified.
Timeline
- Start
- 2024-11-27
- Primary completion
- 2028-12-02
- Completion
- 2029-12-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glofitamab | Monoclonal antibody | — | Intravenous |
| Subject | Mosunetuzumab | Monoclonal antibody | — | Subcutaneous |
| Subject | Sonrotoclax | Other / unclassified | — | Oral |
| Subject | Tacabrutideg | Unknown | — | Oral |
| Subject | Zanubrutinib | Small molecule | — | Oral |
| Background | Obinutuzumab | Monoclonal antibody | — | Intravenous |